The Efficacy and Safety of Imeglimine in Elderly People with Type 2 Diabetes Mellitus

The Efficacy and Safety of Imeglimine in Elderly People with Type 2 Diabetes Mellitus - Imeglimin in Elderly Diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000050556

Enrollment

Registered

2023-03-11

Start date

2023-03-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly people with type 2 diabetes (65 years and older)

Interventions

Imeglimin 2000 mg a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) People with type 2 diabetes over 65 years old 2) HbA1c of 6.5% to 10.0% before intervention (4 to 8 weeks ago) 3) People scheduled to receive Imeglimine who have an indication to use Imeglimine

Exclusion criteria

Exclusion criteria: 1) Patients on multiple insulin injection therapy (basal and bolus insulin therapy) 2) Patients with renal dysfunction (glomerular filtration rate (eGFR) <45 mL/min/1.73 m2) 3) Patients with severe anemia (Hb < 10g/dL) 4) Patients who are using an implantable medical device (e.g. pacemaker) 5) Patients with severe cognitive impairment 6) Patients with active malignant tumors 7) Patients who are judged by the principal investigator or subinvestigator to be inappropriate to participate in this clinical research

Design outcomes

Primary

Measure	Time frame
Glycemic profilse after treatment with Imeglimin	—

Countries

Japan

Contacts

Public ContactRei Fujishima

Kitasato University School of Medicine Endocrinology, Diabetes and Metabolism

ahayashi@kitasato-u.ac.jp0427788111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026